FactSet Stock Downgraded to Sell, Price Target Reduced on Terminal Risks

Rothschild & Co Redburn downgraded FactSet Research Systems (FDS) from Neutral to Sell, cutting the price target to $215 from $291, citing structural "terminal risks" including AI disruption and intensifying competition from Bloomberg and LSEG.

Rothschild & Co Redburn dropped its rating on FDS to Sell from Neutral on June 18, 2026, slashing the price target to $215 from $291. The 26% target reduction reflects what the firm called "terminal risks": a structural thesis that the financial-data terminal model underpinning FactSet's business is being eroded by AI disintermediation, intensifying competition, and changing consumption patterns among its core asset management clientele.

The concern centers on how financial professionals access and pay for market data. FactSet derives a substantial portion of its annual subscription value from terminal-based workflows -- an area now under pressure from AI-powered aggregators, unbundled data alternatives, and formidable rivals. Bloomberg retains deep market penetration reinforced by its messaging network, while LSEG (having absorbed Refinitiv) competes aggressively on breadth and pricing. Analysts at Rothschild Redburn estimate their 2026-28 earnings per share projections sit roughly 4% below consensus, suggesting the Street has not fully priced in the headwinds. FDS shares have declined approximately 30% in 2026, and the $215 target implies further downside from current levels.

The key question for investors is whether FactSet can reposition fast enough to offset terminal attrition. The company has signaled awareness of the AI shift, including integrating its financial database with large language model platforms. But the structural challenge is not a single product gap: it is whether an incumbent built on terminal subscriptions can defend pricing power against a generation of AI tools that commoditize data retrieval. Watchers should track renewal rates, average revenue per user trends, and the pace of any client consolidation or headcount reductions across the buy side -- the clearest leading indicators of whether terminal-risk concerns are materializing or proving overstated.

Powered by SentiSense - Intelligent Market Analysis